Benzophenonoxim-O-isopropylether | 61582-66-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: Benzophenonoxim-O-isopropylether
• 英文别名: Benzophenon-O-isopropyloxim；1,1-diphenyl-N-propan-2-yloxymethanimine
• CAS: 61582-66-9
• 化学式: C₁₆H₁₇NO
• 分子量: 239.317
• InChiKey: IHWKCPMHVMROIP-UHFFFAOYSA-N

物化性质

• 沸点：
  338.3±25.0 °C(Predicted)
• 密度：
  0.98±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  21.6
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  二苯甲酮肟 、 异丙醇 在 四氯化碳 、 四丁基碘化铵 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 、 三苯基膦 作用下， 以 乙腈 为溶剂， 反应 9.0h， 以52%的产率得到Benzophenonoxim-O-isopropylether
  参考文献：
  名称：

  使用三苯基膦/四氯化碳从醇高效一锅合成肟醚

  摘要：

  描述了在三氯化碳中使用三苯基膦方便有效地从醇中进行肟的一锅O-烷基化。在这种方法中，在回流的乙腈中，在催化量的碘化四丁铵存在下，用三苯基膦，四氯化碳，肟和DBU的混合物处理醇，可以高收率提供相应的O-烷基醚。该方法是用各种结构多样的醇对肟进行高效的O-烷基化。对于不对称肟醚的半经验量子力学计算（AM1）表明Z异构体的形成热较低。 肟-醇-O-烷基化-三苯基膦-四氯化碳-DBU

  DOI：

  10.1055/s-0029-1218711

文献信息

• Forrester,A.R. et al., Journal of the Chemical Society. Perkin transactions I, 1979, p. 606 - 611
  作者：Forrester,A.R. et al.

  DOI：——

  日期：——
• ACYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS
  申请人：Sun Ying

  公开号：US20080125444A1

  公开（公告）日：2008-05-29

  The present invention discloses compounds of formula I or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
• OXIMYL HCV SERINE PROTEASE INHIBITORS
  申请人：GAI YONGHUA

  公开号：US20090155210A1

  公开（公告）日：2009-06-18

  The present invention discloses compounds of formula I or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
• FLUORINATED TRIPEPTIDE HCV SERINE PROTEASE INHIBITORS
  申请人：GAI YONGHUA

  公开号：US20090197888A1

  公开（公告）日：2009-08-06

  The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis c virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis c virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
• US7728148B2
  申请人：——

  公开号：US7728148B2

  公开（公告）日：2010-06-01